As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The Oncology Division of Hetero Healthcare is dedicated to providing specialized therapeutic solutions for the management of various types of cancer. Its portfolio supports oncology care across different stages of treatment, addressing the complex and evolving needs of patients and healthcare professionals.
The division encompasses therapies across chemotherapy, targeted therapy, hormonal therapy, immuno-oncology, and supportive cancer care, catering to multiple oncological conditions and treatment requirements.
Backed by Hetero Healthcare’s commitment to quality, accessibility, and patient-centric care, the Oncology Division strives to make advanced cancer therapies more accessible while supporting comprehensive treatment and better patient outcomes.
View by-
